BALTIMORE (Stockpickr) -- It's earnings season, and so far, the numbers are looking impressive. Out the gate, 70% of early reportingS&P 500 names have met or beat earnings expectations. But a whopping 78% of individual names in the big index are down over that same stretch, since earnings season started.
>>5 Toxic Stocks You Need to Sell in July
The clear takeaway is the earnings don't matter as much as most investors think -- at least not in their raw form.
But while the price direction from quarterly financial releases is far from obvious, earnings can certainly inject volatility into the marketplace. Last week was the fourth-biggest drop of 2014, and two of the other four took place during earnings season as well. Want to navigate the noise? Then focus on the "Rocket Stocks."
For the uninitiated, "Rocket Stocks" are our list of companies with short-term gain catalysts and longer-term growth potential. To find them, I run a weekly quantitative screen that seeks out stocks with a combination of analyst upgrades and positive earnings surprises to identify rising analyst expectations, a bullish signal for stocks in any market. After all, where analysts' expectations are increasing, institutional cash often follows. In the last 257 weeks, our weekly list of five plays has outperformed the S&P 500 by 79.51%.
Best Long Term Companies To Invest In Right Now: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Sean Williams]
Biotechnology juggernaut Pharmacyclics (NASDAQ: PCYC ) -- a company that has returned close to 19,000% since its recession lows -- ignited investor optimism when it and licensing partner Johnson & Johnson (NYSE: JNJ ) filed a new drug application for ibrutinib. This is truly exciting news, because it marks the first breakthrough therapy drug that's filed for an NDA, and will act the test subject to the rest of the breakthrough therapy designated drugs. Ibrutinib delivered exceptional results in chronic lymphocytic leukemia and mantle cell lymphoma in terms of overall response rate, which should probably net it an approval from the Food and Drug Administration.
- [By Jay Silverman]
Over the past year, including the end of this year, we've had new blockbuster drugs for hepatitis C, which is Gilead's (GILD) drug, and also for B-cell lymphomas, which is Pharmacyclics' (PCYC) drug. Those are looking to be two of the biggest drugs ever.
- [By Jon C. Ogg]
Pharmacyclics Inc. (NASDAQ: PCYC) was started as Overweight with a $142 price target at J.P. Morgan. Deutsche Bank also started it with a Buy rating and a $170 price target.
- [By Mani]
Pharmacyclics, Inc. (NASDAQ: PCYC) is one of the best ways to play the hematology cancer drug market as its Ibrutinib is expected to transform the treatment of many blood cancers.
Top 10 Rising Stocks To Watch Right Now: Newcrest Mining Ltd (NCMGF)
Newcrest Mining Limited (Newcrest) is a gold, copper and silver producer that has operations and exploration projects in Australia, the Pacific region, Asia and West Africa. The Company�� segments include Cadia Valley, Telfer, Gosowong, Lihir, Hidden Valley JV, West Africa (includes Bonikro operations and exploration and evaluation activities in Cote d��voire) and Exploration and Other. Exploration and Other mainly consists of projects in the exploration, evaluation and feasibility phase and includes Namosi in Fiji, Wafi Golpu in Papua New Guinea (PNG), and Marsden and O��allaghans in Australia. Cadia Valley Operations (CVO) is a gold mining operation and is 100% owned by Newcrest. It is located approximately 25 kilometers from the city of Orange in central west New South Wales and is 250 kilometers west of Sydney. Advisors' Opinion:- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Australian stocks rose in early Monday trading, helped by Wall Street's gains Friday, with the S&P/ASX 200 (AU:XJO) climbing 0.8% to 5,362.40 after closing the previous session at its highest level since before the start of the 2008 financial crisis. Miners were broadly improving, as Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) rose 1.3%, BHP Billiton Ltd. (AU:BHP) (BHP) added 0.9% ahead of its quarterly production report Tuesday, and Newcrest Mining Ltd. (AU:NCM) (NCMGF) also climbed 0.9% despite a loss for gold at the end of last week. Financials saw gains as well, with many analysts now tipping the U.S. Federal Reserve to maintain its current level of easing through the end of the year. Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) advanced 1.1%, while Westpac Banking Corp. (AU:WBC) (WEBNF) and Macquarie Group Ltd. (AU:MQG) (MCQEF) rose 1.2% each. On the downside, shares of Qantas Airways Ltd. (AU:QAN) (QUBSF) fell 4.2% after the company warned of rough business conditions on Friday.
Top 10 Rising Stocks To Watch Right Now: Ingram Micro Inc. (IM)
Ingram Micro Inc. distributes information technology (IT) products; and provides supply chain solutions, mobile device lifecycle services, and logistics solutions worldwide. The company�s IT peripherals include printers, scanners, displays, projectors, monitors, panels, mass storage, and tape; large format LCD and plasma displays, enclosures, mounts, media players, content software, and content creation and hosting; mobile phones, digital cameras and video disc players, game consoles, televisions, audio, media management, and home control products; barcode/card printers, AIDC scanners and software, and wireless infrastructure products; IP video surveillance, security and fire alarm systems, and access control smart cards; processors, motherboards, hard drives, and memory products; and ink and toner supplies, paper, carrying cases, and anti-glare screens. It also provides various systems, including rack, tower, and blade servers; desktops; portable personal computers and t ablets; and software products, such as business application, operating system, entertainment, security, storage, and virtualization software products, as well as middleware and developer software tools. The company�s networking products comprise switches, hubs, routers, wireless local area networks, wireless wide area networks, network interface cards, cellular data cards, network-attached storage, and storage area networks; voice over Internet protocol, communications, modems, phone systems, and video/audio conferencing; and firewalls, virtual private networks, intrusion detection, and authentication devices and appliances. In addition, it provides integration, technical support, training, financial and credit, marketing, predictive analytics, eCommerce, reseller community hosting, managed, cloud, managed print, and professional services. The company sells its products to resellers through sales representatives. Ingram Micro Inc. was founded in 1979 and is headquartered in Santa Ana, California.
Advisors' Opinion:- [By Keith Speights]
My take is that Qualcomm has rapidly established itself as the de facto standard for connecting with medical devices. The company isn't doing it alone, though. It teamed with Ingram Micro (NYSE: IM ) , the world's largest technology distributor, to support the implementation, logistics, and financial services related to the 2net hub and platform. This partnership should help propagate Qualcomm's technology more effectively than the company could have done on its own.
- [By Geoff Gannon]
A huge net-net like Ingram Micro (IM) with nine out of ten years of profits in the last decade is pretty unusual. And Ingram operates on a razor-thin margin. It usually makes about one cent in profit for every dollar of sales.
Top 10 Rising Stocks To Watch Right Now: Sanofi(SNY)
sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.
Advisors' Opinion:- [By Dan Carroll]
Major electronics companies such as Samsung and Jabil Circuit (NYSE: JBL ) , which is planning on tripling its workforce in its factory in Ho Chi Minh City over the next two years and has cited China's rising costs as a primary driver of the move away from the nation, have seized the opportunity to slash costs even with Vietnam still lagging behind China in terms of productivity. Even sectors such as health care have gotten involved, as pharmaceutical company Sanofi (NYSE: SNY ) this year announced plans to invest $75 million in a Vietnamese facility to serve as an emerging-markets hub and entrench its leadership position in Southeast Asia.
Top 10 Rising Stocks To Watch Right Now: Pacific Drilling SA (PACD)
Pacific Drilling S.A., incorporated on March 22, 2011, is an international offshore drilling Company. The Company is a provider of ultra-deepwater drilling services to the oil and natural gas industry through the use of high-specification drilling rigs. The Company�� primary business is to contract its ultra-deepwater drilling rigs, related equipment and work crews, primarily on a dayrate basis, to drill wells for its customers. The Company is primarily focused on the ultra-deepwater market. The Company generally consider ultra-deepwater to begin at water depths of more than 7,500 feet and to extend to the maximum water depths, in which rigs are capable of drilling, which is approximately 12,000 feet.
The Company operates four drillships and has four drillships under construction, two of which are under customer contract. In connection with the Restructuring, the Company�� Predecessor was contributed to a wholly owned subsidiary of the Company by a subsidiary of Quantum Pacific International Limited.
Advisors' Opinion:- [By Roberto Pedone]
Pacific Drilling (PACD) is an international offshore drilling contractor committed to becoming the preferred provider of ultra-deepwater drilling services to the oil and natural gas industry through the use of high-specification rigs. This stock closed up 1% to $9.94 in Thursday's trading session.
Thursday's Range: $9.87-$10.00
52-Week Range: $8.63-$10.99
Thursday's Volume: 450,000
Three-Month Average Volume: 308,772From a technical perspective, PACD bounced modestly higher here right above its 50-day moving average of $9.67 with above-average volume. This stock has been trending sideways and consolidating for the last five months, with shares moving between $8.89 on the downside and $10.23 on the upside. Shares of PACD are now starting to trend within range of triggering a breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if PACD manages to take out some key overhead resistance levels at $10.14 to $10.23 with high volume.
Traders should now look for long-biased trades in PACD as long as it's trending above its 50-day at $9.81 and then once it sustains a move or close above those breakout levels with volume that hits near or above 308,772 shares. If that breakout triggers soon, then PACD will set up to re-test or possibly take out its next major overhead resistance levels at $10.71 to its 52-week high at $10.99. Any high-volume move above $10.99 will then put its all-time high at $11.47 within range for shares of PACD.
- [By David Smith]
Chevron has been working hand-in-glove in implementing DGD with offshore rig operator Pacific Drilling (NYSE: PACD ) . Pacific's drillship Pacific Santa Ana was specifically built to Chevron's DGD-enhancing specifications and is working for the big company in the Gulf of Mexico.
- [By Ben Levisohn]
On the surface, offshore drilling stocks appear inexpensive with multiples at the low end of historical ranges and many stocks trading below book values. While contrarian and deep value players are beginning to nibble, we believe the offshore floating rig companies are still in the early innings of a cyclical downturn in utilization and dayrates. After a decade of good times, the deepwater drilling rig market is facing a multiyear down-cycle. Historically, most offshore drilling cycles have been short-lived as there have usually been sudden demand shocks that tend to self correct relatively quickly. This time, it is more of a new rig supply problem compounded by a moderation in offshore spending from the suddenly ��eturn driven��multinational major oil companies. That means this down-cycle should be more drawn out than usual. Specifically, we think the downturn will take about three years to play out with average floater day-rates falling about 25% with over 60 floating rigs needing to be stacked (either warm stacked or cold stacked). More importantly for investors, we think consensus 2016 floater estimates (on average) are still about 25% too high. Put another way, earnings multiples are not as attractive as some now think, in our view. Obviously, the lower-end, older floating assets will be hit the hardest. While everyone loses in this environment, we are more comfortable in owning companies with higher-quality assets that also carry higher floater contract coverage, as we expect this to provide relative safety during this downturn. Specifically, we relatively favor Ocean Rig UDW (ORIG), Pacific Drilling (PACD), and Rowan, given their high-specification exposure. Of course, this downturn is not limited to the floater side of the offshore arena. Next week, we will detail our expectations for the timing and magnitude of the utilization and dayrate declines for the offshore jackup space.
- [By Aaron Levitt]
Management recently announced a hefty 50% hike in its quarterly dividend to 37.5 cents per share of NE stock. And with a 4.8% dividend yield, NE stock is now one of the best-paying dividend stocks in the energy sector.
Dividend Stocks To Buy #5 — Pacific Drilling (PACD)Estimated Dividend Yield: 6.5%
Top 10 Rising Stocks To Watch Right Now: Genesco Inc. (GCO)
Genesco Inc. engages in the retail and wholesale of footwear, apparel, and accessories. The company operates in five segments: Journeys Group, Schuh Group, Lids Sports Group, Johnston & Murphy Group, and Licensed Brands. The Journeys Group segment operates the Journeys, Journeys Kidz, Shi by Journeys, and Underground by Journeys retail stores that provide footwear and accessories for men, women, and younger children. It also sells footwear and accessories through direct-to-consumer catalog and e-commerce operations. The Schuh Group segment operates Schuh retail footwear stores, which offer casual and athletic footwear for 15 to 30 year old men and women, as well as engages in the e-commerce operations. The Lids Sports Group segment operates headwear and accessory stores under the Lids, Hat World, and Hat Shack banners; sports-oriented fan shops that offer licensed merchandise, such as apparel, hats and accessories, sports decor, and novelty products under the Lids Locker R oom, Sports Fan-Attic, and Sports Avenue banners; and as a Lids Team Sports athletic team dealer, as well as in e-commerce operations. The Johnston & Murphy Group segment is involved in Johnston and Murphy retail, catalog and e-commerce, and wholesale distribution operations. Its stores provide footwear, luggage, and accessories for business and professional customers. The Licensed Brands segment markets casual and dress footwear under the Dockers brand for men aged 30 to 55. As of May 31, 2013, the company operated 2,455 retail stores in the United States, Canada, the United Kingdom, and the Republic of Ireland. The company also sells its products through journeys.com, journeyskidz.com, shibyjourneys.com, undergroundbyjourneys.com, schuh.co.uk, and johnstonmurphy.com. Genesco Inc. was founded in 1924 and is headquartered in Nashville, Tennessee.
Advisors' Opinion:- [By Reuters]
Steven Senne/AP BOSTON -- Companies that help Target process payments could face millions of dollars in fines and costs resulting from the unprecedented data breach that struck the retailer during the holiday shopping season. Investigators are still sorting through just how thieves compromised about 40 million payment cards and the information of about 70 million Target (TGT) customers. But people who have reviewed past data breaches believe Target's partners could face consumer lawsuits and fines that payment networks such as Visa (V) and MasterCard (MA) often levy after cybersecurity incidents. Target's partners "have deep pockets and are intimately involved in certain aspects of how Target gets paid," said Jamie Pole, a cybersecurity consultant in Asheboro, N.C., who works for government agencies and the financial industry. Fines and settlement costs could reach into the millions of dollars for individual companies, he said, though much will depend on how the ultimate liability for the breach is determined. Boston attorney Cynthia Larose of Mintz Levin said Target would likely seek to add its partners as defendants to lawsuits already filed over the breach. "These class-action lawsuits start to bring everyone in at some point," she said. After its systems were penetrated by hackers in the mid-2000s, retailer TJX Cos. (TJX) agreed to pay up to $40.9 million to cover fraud costs in a settlement with Visa. Visa also issued penalties of $880,000 against Fifth Third Bancorp (FITB) of Ohio, which processed transactions for TJX. Asked about the business relationships and possible costs, Target spokeswoman Molly Snyder declined to comment, citing the ongoing investigation and pending suits. A Visa spokeswoman declined to comment. A MasterCard spokesman said the company couldn't discuss an ongoing investigation. Handling Target Transactions Several companies are involved in any purchase from a store such as Target. A bank issues the consumer's payment card
- [By Eric Volkman]
Genesco (NYSE: GCO ) results for the company's fiscal Q1 2014 have been released. For the quarter, net sales came in at $591 million, a drop of 1.5% from the $600 million in the same period the previous year. Net profit also saw a slip, to $18.4 million ($0.77 per diluted share) from Q1 2013's figure of $20.6 million ($0.85). On an adjusted basis, those numbers were $22.2 million ($0.94 per diluted share) and $23.8 ($0.98), respectively.
Top 10 Rising Stocks To Watch Right Now: Templeton Emerging Markets Fund (EMF)
Templeton Emerging Markets Fund (the Fund) is a diversified, closed-end investment company. The Fund seeks long-term capital appreciation by investing at least 80% of its net assets in emerging country equity securities. It makes investments in China, Brazil, South Korea, Turkey, Russia, Thailand, India, Taiwan, Hungary and South Africa. The Fund invests in sectors, such as metals and mining, commercial banks, diversified financial services, semiconductors and semiconductor equipment, wireless telecommunication services, and oil, gas and consumable fuels.
Templeton Asset Management Ltd. (TAML) serves as the Fund�� investment manager. Its administrative manager is Franklin Templeton Services, LLC. The Fund may invest in the Franklin Institutional Fiduciary Trust Money Market Portfolio (the Sweep Money Fund), an open-end investment company managed by Franklin Advisers, Inc. (an affiliate of TAML).
Advisors' Opinion:- [By George Putnam, Editor, New Generation Research, Inc.]
Templeton Emerging Markets Fund (EMF) is also actively managed. Currently, the fund is Asian-centric with about 71% of assets from Asian markets, mostly China and Thailand.
No comments:
Post a Comment